Akebia Therapeutics (AKBA) Resumen de Acciones
Akebia Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo y la comercialización de terapias para pacientes con enfermedades renales. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
AKBA Community Fair Values
Create NarrativeSee what 48 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$77.29
FV
98.2% infravalorado descuento intrínseco409
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Competidores de Akebia Therapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$1.38 |
| Máximo en las últimas 52 semanas | US$4.04 |
| Mínimo de 52 semanas | US$0.82 |
| Beta | 0.23 |
| Cambio en 1 mes | 49.27% |
| Variación en 3 meses | -11.54% |
| Cambio de 1 año | -65.24% |
| Variación en 3 años | 15.00% |
| Variación en 5 años | -52.08% |
| Variación desde la OPV | -94.83% |
Noticias y actualizaciones recientes
Recent updates
Actualización de narrativa • Jun 24
Market Anger vs. Valuation Disconnect
The current low price is driven by market fury over management's failure to handle an expected product transition. By reacting emotionally to a temporary operational blunder, the market has created a massive disconnect between Akebia's current price and its true intrinsic value.
Actualización de narrativa • Jun 22
AKBA: Extended Kidney Patent Protection Will Support Future Upside Potential
Analysts have adjusted their price target for Akebia Therapeutics to $6.00, citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E, which together support this revised valuation view. What’s in the News for Akebia Therapeutics Akebia Therapeutics was removed from the S&P Biotechnology Select Industry Index, reflecting a change in index membership based on that provider’s criteria.Actualización de narrativa • Jun 05
AKBA: Kidney Pipeline Expansion And Share Authorization Increase Will Support Upside Potential
Analysts have maintained their $6.00 price target for Akebia Therapeutics, citing only minor updates in their underlying assumptions on discount rate, revenue growth, profit margins, and future P/E as the reason for no change in the headline number. What's in the News Akebia Therapeutics plans to seek shareholder approval to amend its Ninth Amended and Restated Certificate of Incorporation to increase authorized capital stock to 525,000,000 shares and authorized common stock to 500,000,000 shares.Actualización de narrativa • May 19
AKBA: Kidney Pipeline Advances Will Offset Renal Channel Inventory Adjustments
Narrative Update on Akebia Therapeutics Analysts have trimmed their price target on Akebia Therapeutics stock by $1 to $4, citing a new US Renal Care dosing protocol that they say reduced channel inventory by about $4.5M to $5.0M and contributed to Vafseo revenue recognized in Q4 coming in $5M to $6M lower than they had expected. Analyst Commentary Bullish analysts are framing the recent price target trim as a fine tuning of expectations rather than a shift in the core thesis on Akebia Therapeutics.Artículo de análisis • May 11
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
There's been a major selloff in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares in the week since it released its...Actualización de narrativa • May 03
AKBA: Kidney Pipeline Progress Will Drive Future Upside Despite Inventory Headwinds
Narrative Update on Akebia Therapeutics Analysts have reduced Akebia Therapeutics' price target by $1 to $4, citing updated expectations for Vafseo revenue after a new US Renal Care dosing protocol and related channel inventory adjustments. Analyst Commentary Bullish analysts appear focused on how recent pricing and dosing updates feed into the long term opportunity for Vafseo, even as they recalibrate near term expectations.
Actualización de narrativa • Apr 19
AKBA: Renal Dosing Reset And Inventory Shift Will Support Future Profitability
Akebia Therapeutics' consensus analyst price target has shifted lower, with moves such as a cut from $5 to $4 at BTIG and a $2 reduction at Piper Sandler as analysts factor in recent Vafseo revenue shortfalls tied to US Renal Care's updated dosing protocol and related channel inventory effects. Analyst Commentary Bearish analysts are reassessing Akebia Therapeutics after Vafseo revenue recognized in Q4 came in at about US$5m to US$6m, which they link to a new US Renal Care protocol and an estimated US$4.5m to US$5m decrease in channel inventory.
Actualización de narrativa • Apr 05
AKBA: Phase 2 Kidney Trial Will Offset Dosing Protocol Revenue Reset
Akebia Therapeutics' Street price targets have been trimmed by analysts, with one firm moving from $5 to $4 as they factor in lower than expected Q4 Vafseo revenue tied to a new US Renal Care dosing protocol and related channel inventory reductions. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after trimming price targets.Actualización de narrativa • Mar 22
AKBA: Renal Care Dosing Reset Will Support Stronger Long Term Profitability
Akebia Therapeutics' consensus analyst price target has moved lower to $4 from $5, as analysts factor in recent updates on Vafseo revenue recognition tied to US Renal Care dosing protocols and related channel inventory adjustments. Analyst Commentary Bearish analysts are framing the lower $4 price target as a reflection of execution risk around the Vafseo launch, especially after the new US Renal Care dosing protocol affected how much revenue could be recognized in the quarter.Nueva narrativa • Mar 13
Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Actualización de narrativa • Mar 07
AKBA: Phase 2 Kidney Disease Trial And Dosing Reset Will Drive Upside
Narrative Update Akebia Therapeutics' consensus analyst price target has shifted from about $5 to roughly $4.40, as analysts factor in the recent US Renal Care dosing protocol change and its impact on Vafseo channel inventory and recognized Q4 revenue. Analyst Commentary Recent research updates reflect a mixed read on Akebia Therapeutics, with targets adjusted to roughly US$4, as analysts factor in the new US Renal Care dosing protocol and its effect on Vafseo revenue recognition in Q4.Actualización de narrativa • Feb 21
AKBA: Rare Kidney Pipeline Progress Will Support Stronger Long Term Profitability
Analysts have reduced their Akebia Therapeutics price target by $3, citing a lower fair value estimate, a higher discount rate, and a shift to expectations of declining revenue growth. This is partly offset by a slightly stronger profit margin outlook and a lower assumed future P/E multiple.Actualización de narrativa • Feb 07
AKBA: Phase 2 Kidney Disease Pipeline Progress Will Drive Substantial Upside
Analysts have trimmed their fair value estimate for Akebia Therapeutics from US$5.40 to US$5.00, citing updated assumptions for growth, profitability and a higher future P/E multiple reflected in recent Street research, including the lowered Piper Sandler price target. Analyst Commentary Recent research around Akebia Therapeutics has focused on how updated growth and profitability assumptions feed into valuation, including the trimmed fair value estimate and a reset price target.Actualización de narrativa • Jan 24
AKBA: Rare Kidney Disease Pipeline Progress Will Drive Future Upside
Analysts now set their price target for Akebia Therapeutics at US$6.00, unchanged from the prior US$6.00. This reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E that largely offset each other in their valuation work.Actualización de narrativa • Jan 10
AKBA: Rare Kidney Pipeline And Anemia Data Will Support Future Upside
Analysts have adjusted their price target on Akebia Therapeutics to US$6.00 from US$6.00, reflecting updated assumptions around the discount rate, expected revenue growth, profit margin and a slightly higher future P/E multiple. What's in the News Akebia dosed the first patient in a Phase 2 randomized, double blind, placebo controlled trial of praliciguat for biopsy confirmed focal segmental glomerulosclerosis.Actualización de narrativa • Dec 26
AKBA: Rare Kidney Pipeline Progress Will Drive Future Share Upside
Analysts have nudged their price target for Akebia Therapeutics slightly higher to 6.00 dollars per share from 6.00 dollars previously, reflecting modestly improved long term assumptions around revenue growth, profit margins, and the companys risk profile. What's in the News Akebia has initiated Phase 2 clinical development of praliciguat for focal segmental glomerulosclerosis, triggering an expected 1.0 million dollar regulatory milestone payment to Cyclerion when the first patient is dosed, anticipated in 2026 (Key Developments).Actualización de narrativa • Dec 12
AKBA: Rare Kidney Franchise Will Drive Future Share Upside Despite Higher Risk
Analysts have reduced their fair value estimate for Akebia Therapeutics from 10.00 dollars to 6.00 dollars, citing a higher perceived risk profile. This is reflected in an increased discount rate and a lower future earnings multiple, even as long term revenue growth and margin expectations edge higher.Actualización de narrativa • Nov 28
AKBA: European Partnership And Clinical Data Will Drive Substantial Upside
Analysts have slightly lowered their price target for Akebia Therapeutics from $5.50 to $5.40, citing updated financial forecasts, as well as expectations for improved profit margins and revenue growth. What's in the News Akebia Therapeutics and Medice amended their License Agreement and granted Medice the right to manufacture Vafseo tablets for anemia in chronic kidney disease patients in Europe.Actualización de narrativa • Nov 13
AKBA: Broad U.S. Launch In 2025 Will Drive Upside Potential
Analysts have lowered their price target for Akebia Therapeutics from $6.80 to $5.50, citing moderated expectations for revenue growth and profitability. What's in the News Akebia Therapeutics presented a post-hoc win odds analysis from the Phase 3 INNO2VATE trials of vadadustat, showing favorable effects of Vafseo compared to darbepoetin alfa on death or hospitalization in dialysis patients.Artículo de análisis • Nov 04
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive
Unfortunately for some shareholders, the Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) share price has dived 25% in the...Actualización de narrativa • Oct 30
AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside
Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.Artículo de análisis • Aug 10
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?
NasdaqCM:AKBA 1 Year Share Price vs Fair Value Explore Akebia Therapeutics's Fair Values from the Community and select...Artículo de análisis • Jun 18
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...Artículo de análisis • May 10
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Investors in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) had a good week, as its shares rose 4.1% to close at US$2.55...Artículo de análisis • May 04
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...
Nueva narrativa • Apr 28
Vafseo And VALOR Study Will Open New Treatment Markets
Early success of Vafseo and reimbursement coverage expansion likely to drive strong revenue growth and market access.Artículo de análisis • Mar 20
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have continued their recent momentum with a 33% gain in the last month...Artículo de análisis • Mar 16
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Shareholders of Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) will be pleased this week, given that the stock price is up...Artículo de análisis • Jan 22
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Artículo de análisis • Nov 08
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Rentabilidad de los accionistas
| AKBA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 6.2% | -3.1% | -0.9% |
| 1Y | -65.2% | 32.8% | 19.4% |
Rentabilidad vs. Industria: Los resultados de AKBA fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 32.8% el año pasado.
Rentabilidad vs. Mercado: AKBA obtuvo unos resultados inferiores a los del mercado US, que fueron del 19.4% el año pasado.
Volatilidad de los precios
| AKBA volatility | |
|---|---|
| AKBA Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de AKBA ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de AKBA(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 194 | John Butler | www.akebia.com |
Akebia Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo y la comercialización de productos terapéuticos para pacientes con enfermedades renales. Su cartera de productos incluye Vafseo (vadadustat), una prolil hidroxilasa oral del factor inducible por hipoxia, para el tratamiento de la anemia debida a la enfermedad renal crónica (ERC) en pacientes dependientes de diálisis (DD) y no dependientes de diálisis (NDD); y Auryxia, un citrato férrico que se utiliza para controlar los niveles séricos de fósforo en pacientes adultos con ERC-DD y el tratamiento de la anemia ferropénica en pacientes adultos con ERC-NDD. La empresa también está desarrollando AKB-9090, que se encuentra en fase 2 de ensayo clínico para el tratamiento de la lesión renal aguda relacionada con la cirugía cardíaca y el síndrome de dificultad respiratoria aguda; y AKB-10108 para el tratamiento de la retinopatía del prematuro en neonatos.
Resumen de fundamentos de Akebia Therapeutics, Inc.
| Estadísticas fundamentales de AKBA | |
|---|---|
| Capitalización bursátil | US$375.56m |
| Beneficios(TTM) | -US$20.51m |
| Ingresos (TTM) | US$232.40m |
1.6x
Ratio precio-ventas (PS)-18.0x
Ratio precio-beneficio (PE)¿Está AKBA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AKBA | |
|---|---|
| Ingresos | US$232.40m |
| Coste de los ingresos | US$41.97m |
| Beneficio bruto | US$190.43m |
| Otros gastos | US$210.94m |
| Beneficios | -US$20.51m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.076 |
| Margen bruto | 81.94% |
| Margen de beneficio neto | -8.83% |
| Ratio deuda/patrimonio | 713.8% |
¿Cómo se ha desempeñado AKBA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/13 13:25 |
| Precio de las acciones al final del día | 2026/07/13 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Akebia Therapeutics, Inc. está cubierta por 17 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Julian Harrison | BTIG |
| Michael King | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |